Nasdaq: REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker REGN. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
REGN
Exchange
Nasdaq
SEC CIK
872589
Official filings
SEC EDGAR

Research REGN

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Regeneron Pharmaceuticals, Inc.'s stock ticker?

Regeneron Pharmaceuticals, Inc. trades under the ticker symbol REGN on Nasdaq. Its SEC Central Index Key (CIK) is 872589.

Where can I read Regeneron Pharmaceuticals, Inc.'s SEC filings?

The REGN SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Regeneron Pharmaceuticals, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze REGN's financial statements?

The REGN Financials page shows Regeneron Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does REGN compare with its peers and the market?

The REGN Peer Comparison page lines Regeneron Pharmaceuticals, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500 and Nasdaq.

For information only — not investment advice.